Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 82.68
(-0.39%)
INR 82.68
(-0.39%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.65 Billion INR | -36.13% |
| 2022 | 18.24 Billion INR | 1.29% |
| 2021 | 18 Billion INR | -0.97% |
| 2020 | 18.18 Billion INR | -2.76% |
| 2019 | 18.7 Billion INR | -2.8% |
| 2018 | 19.23 Billion INR | -6.86% |
| 2017 | 20.65 Billion INR | -3.36% |
| 2016 | 21.37 Billion INR | -3.68% |
| 2015 | 22.19 Billion INR | -1.1% |
| 2014 | 22.43 Billion INR | -3.27% |
| 2013 | 23.19 Billion INR | -2.29% |
| 2012 | 23.74 Billion INR | 7.66% |
| 2011 | 22.05 Billion INR | 27.23% |
| 2010 | 17.33 Billion INR | 36.01% |
| 2009 | 12.74 Billion INR | 32.73% |
| 2008 | 9.6 Billion INR | 19.16% |
| 2007 | 8.05 Billion INR | 15.48% |
| 2006 | 6.97 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 11.65 Billion INR | 0.0% |
| 2023 Q2 | 17.99 Billion INR | 0.0% |
| 2023 FY | 11.65 Billion INR | -36.13% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 18.24 Billion INR | 1.29% |
| 2022 Q4 | 18.24 Billion INR | 0.0% |
| 2022 Q2 | 18.17 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 18 Billion INR | -0.97% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 18.23 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 18 Billion INR | 0.0% |
| 2020 Q4 | 18.18 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 18.18 Billion INR | -2.76% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 18.77 Billion INR | 0.0% |
| 2019 Q4 | 18.7 Billion INR | 0.0% |
| 2019 Q2 | 18.73 Billion INR | 0.0% |
| 2019 FY | 18.7 Billion INR | -2.8% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 19.23 Billion INR | -6.86% |
| 2018 Q4 | 19.23 Billion INR | 0.0% |
| 2017 FY | 20.65 Billion INR | -3.36% |
| 2016 FY | 21.37 Billion INR | -3.68% |
| 2015 FY | 22.19 Billion INR | -1.1% |
| 2014 FY | 22.43 Billion INR | -3.27% |
| 2013 FY | 23.19 Billion INR | -2.29% |
| 2012 Q4 | 23.74 Billion INR | 0.0% |
| 2012 FY | 23.74 Billion INR | 7.66% |
| 2012 Q2 | 45.14 Billion INR | 0.0% |
| 2011 FY | 22.05 Billion INR | 27.23% |
| 2010 FY | 17.33 Billion INR | 36.01% |
| 2009 FY | 12.74 Billion INR | 32.73% |
| 2008 FY | 9.6 Billion INR | 19.16% |
| 2007 FY | 8.05 Billion INR | 15.48% |
| 2006 FY | 6.97 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 81.924% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 97.415% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 59.125% |
| Granules India Limited | 55.2 Billion INR | 78.897% |
| Indoco Remedies Limited | 21.44 Billion INR | 45.676% |
| Achyut Healthcare Limited | 309.52 Million INR | -3664.212% |
| Ajanta Pharma Limited | 46.38 Billion INR | 74.881% |
| Alkem Laboratories Limited | 155.74 Billion INR | 92.519% |
| Alpa Laboratories Limited | 1.82 Billion INR | -537.989% |
| Brooks Laboratories Limited | 904.45 Million INR | -1188.187% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -8.078% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -52.276% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 4.017% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 96.993% |
| Eris Lifesciences Limited | 70.48 Billion INR | 83.471% |
| FDC Limited | 24.68 Billion INR | 52.793% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 91.886% |
| Gufic Biosciences Limited | 10.92 Billion INR | -6.642% |
| Ipca Laboratories Limited | 111.01 Billion INR | 89.505% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -436.722% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -553.912% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -672.265% |
| Laurus Labs Limited | 83.87 Billion INR | 86.108% |
| Lupin Limited | 239.97 Billion INR | 95.145% |
| Mankind Pharma Limited | 119.63 Billion INR | 90.261% |
| Medicamen Biotech Limited | 2.94 Billion INR | -295.592% |
| Medico Remedies Limited | 961.95 Million INR | -1111.188% |
| Megasoft Limited | 3.65 Billion INR | -218.422% |
| NATCO Pharma Limited | 69.06 Billion INR | 83.13% |
| Piramal Pharma Limited | 153.11 Billion INR | 92.391% |
| RPG Life Sciences Limited | 5.12 Billion INR | -127.174% |
| Sigachi Industries Limited | 6.94 Billion INR | -67.845% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 98.637% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 48.311% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -187.92% |
| Unichem Laboratories Limited | 31.69 Billion INR | 63.238% |
| Wanbury Limited | 3.43 Billion INR | -239.194% |
| Windlas Biotech Limited | 6.26 Billion INR | -86.058% |
| ZIM Laboratories Limited | 4.46 Billion INR | -160.754% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 96.021% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -126.217% |
| Divi's Laboratories Limited | 154.7 Billion INR | 92.469% |
| Hester Biosciences Limited | 6.62 Billion INR | -75.906% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -46.672% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -217.58% |
| Bal Pharma Limited | 3.2 Billion INR | -263.654% |
| Strides Pharma Science Limited | 58.39 Billion INR | 80.049% |
| Venus Remedies Limited | 6.26 Billion INR | -85.873% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 54.878% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 46.824% |
| Shilpa Medicare Limited | 30.93 Billion INR | 62.333% |
| Aarti Drugs Limited | 24.32 Billion INR | 52.1% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 48.088% |
| Suven Life Sciences Limited | 2.84 Billion INR | -308.949% |
| Ind-Swift Limited | 6.54 Billion INR | -78.023% |
| Valiant Laboratories Limited | 3.42 Billion INR | -239.991% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 70.83% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 50.441% |
| Themis Medicare Limited | 5.66 Billion INR | -105.698% |
| Hikal Limited | 24.87 Billion INR | 53.155% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 92.264% |
| Sequent Scientific Limited | 15.4 Billion INR | 24.363% |
| Novartis India Limited | 9.24 Billion INR | -25.967% |
| Wockhardt Limited | 76.49 Billion INR | 84.768% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 89.911% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -2374.595% |
| Neuland Laboratories Limited | 18.32 Billion INR | 36.422% |
| Morepen Laboratories Limited | 12.93 Billion INR | 9.906% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -385.336% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -249.437% |